Sharekhan

Solara Active Pharma Sciences Ltd

Thu 11/09/2025,11:59:55 | NSE : SOLARA

₹ 686.7522.80 (3.43%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 665.00

Previous Close

₹ 663.95

Volume

56791

Mkt Cap ( Rs. Cr)

₹3054.00

High

₹ 688.00

Low

₹ 662.20

52 Week High

₹ 882.80

52 Week Low

₹ 442.80

Book Value Per Share

₹ 245.77

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Solara Active Pharma Sciences Ltd

Your Vote -

Buy

88.24%

Hold

5.29%

Sell

6.47%

88.24%

170 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

43%

Sell Order Quantity

57%

Bid Price

Qty

687.70

6

688.00

5

688.00

6

688.00

12

687.00

1

Bid Total

19841

Bid Price

Qty

688.25

2

689.00

12

689.00

12

689.00

10

689.00

53

Bid Total

26117

Option Chain

Analyzes market sentiment, predicts Solara Active Pharma Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Solara Active Pharma - Copy of Newspaper Publication

    3 Sep 2025, 4:22PM Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Post dispatch Newspaper Publication of 8th AGM Notice
  • Solara Active Pharma - General Updates

    2 Sep 2025, 9:32PM Business Responsibility and Sustainability Report for the Financial year 2024-25
  • Solara Active Pharma - Business Responsibility and Sustainability Reporting (BRSR)

    2 Sep 2025, 9:30PM Business Responsibility and Sustainability Report for the financial year 2024-25.
  • Solara Active Pharma - Reg. 34 (1) Annual Report.

    2 Sep 2025, 9:24PM Annual Report for the financial year ended March 31, 2025.
  • Solara Active Pharma - Shareholders meeting

    2 Sep 2025, 9:12PM Solara Active Pharma Sciences Limited has informed the Exchange about the dispatch of Notice of 8th Annual General Meeting (""AGM"") of the Company.
  • Solara Active Pharma - Notice Of The 8Th Annual General Meeting

    2 Sep 2025, 9:06PM Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of 8th Annual General Meeting (\AGM\) of the Company.
  • Solara Active Pharma - Copy of Newspaper Publication

    1 Sep 2025, 5:24PM Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication with respect to Notice of Annual General Meeting
  • Solara Active Pharma - Updates

    21 Aug 2025, 7:14PM Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding intimation to shareholders as per the 100 Days Campaign - ""Saksham Ni
  • Solara Active Pharma - Intimation Regarding 100 Days Campaign - Saksham Niveshak

    21 Aug 2025, 7:05PM Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding intimation to shareholders as per the 100 Days Campaign - \Saksham Niv
  • Solara Active Pharma - Receipt Of Call Money Pursuant To The First Reminder Notice Issued For Payment Of First Call Money On

    16 Aug 2025, 1:05PM Solara Active Pharma Sciences Limited has informed the Exchange regarding the receipt of first call money pursuant to the First Reminder Notice issued
  • Solara Active Pharma - Updates

    16 Aug 2025, 12:50PM Solara Active Pharma Sciences Limited has informed the Exchange regarding receipt of call money pursuant to the First Reminder Notice issued for payme
  • Solara Active Pharma - Monitoring Agency Report

    13 Aug 2025, 3:53PM Solara Active Pharma Sciences Limited has informed the Exchange regarding submission of Monitoring Agency Report for the quarter ended June 30 , 2025
  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    13 Aug 2025, 3:57PM Solara Active Pharma Sciences Limited has informed the Exchange regarding submission of Monitoring Agency Report for the quarter ended June 30, 2025 r
  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Jul 2025, 4:27PM Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding the Earnings Call Transcript for the Analysts/Investors Conference Cal
  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    29 Jul 2025, 4:06PM Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding the Earnings Call Transcript for the Analysts/Investors conference cal
  • Solara Active Pharma - Copy of Newspaper Publication

    26 Jul 2025, 4:41PM Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication made on July 26 2025 wherein the Financial Results
  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    25 Jul 2025, 6:43PM Solara Active Pharma Sciences Limited has informed the Exchange about Link of Recording of the Investors meet held on 25th July 2025 for the quarter e
  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Jul 2025, 6:41PM SOLARA: Solara Active Pharma Sciences Limited has informed the Exchange about Link of Recording of the Investors meet held on 25th July 2025 for the q
  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    25 Jul 2025, 3:25PM Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated July 25, 2025, titled \ Solara Q'1 26 Performance\ o
  • Solara Active Pharma - Press Release

    25 Jul 2025, 3:19PM Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated July 25, 2025, titled ""Solara Q1'26 performance"" of
  • Solara Active Pharma posts Q1 net profit of Rs 10.53 cr

    25 Jul 2025, 2:10PM The company reported standalone net profit during the quarter stood at Rs 10.53 crore compared to net loss of Rs 12.32 crore in the previous year quar
  • Solara Active Pharma - Statement of deviation(s) or variation(s) under Reg. 32

    25 Jul 2025, 1:41PM Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
  • Solara Active Pharma - Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30

    25 Jul 2025, 1:40PM Solara Active Pharma Sciences Limited has informed the Exchange that there is no Deviation and Variation of Funds raised through Rights issue for Quar
  • Solara Active Pharma - Outcome of Board Meeting

    25 Jul 2025, 1:25PM Solara Active Pharma Sciences Limited has informed the Exchange regarding inter alia, to consider and approve the Unaudited Standalone and Consolidate
  • Solara Active Pharma - Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30, 2025.

    25 Jul 2025, 1:24PM Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidate
  • Solara Active Pharma - Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended

    25 Jul 2025, 1:19PM Solara Active Pharma Sciences Limited has informed the Exchange regarding inter alia, to consider and approve the Unaudited Standalone and Consolidate
  • Solara Active Pharma has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    22 Jul 2025, 7:06AM As of June 2025, 42.01% is owned by Indian Promoters and 57.99% by Public. <p align=justify> Top five Promoters holding highest number of shares of So
  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Jul 2025, 4:49PM SOLARA: Solara Active Pharma Sciences Limited has informed the Exchange about Schedule of Investors/Analyst call to be held on Friday, 25th July 2025
  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Jul 2025, 4:57PM Solara Active Pharma Sciences Limited has informed the Exchange about Schedule of Investors/Analyst call to be held on Friday, 25th July 2025 at 4.00P
  • Solara Active Pharma - Board Meeting Intimation

    18 Jul 2025, 5:41PM SOLARA ACTIVE PHARMA SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 25-Jul-2025 to inter-alia consider and approve the U
  • Solara Active Pharma - Board Meeting Intimation for Quarter Ended June 30, 2025 Under SEBI Listing Regulations

    18 Jul 2025, 5:36PM Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2025 ,inter alia, to
  • Solara Active Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    17 Jul 2025, 5:49PM Solara Active Pharma Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regul
  • Solara Active Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    17 Jul 2025, 5:36PM Solara Active Pharma Sciences Limited has informed the exchange regarding the Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regu
  • Solara Active Pharma - Copy of Newspaper Publication

    7 Jul 2025, 4:44PM Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication made on July 05, 2025
  • Solara Active Pharma - Copy of Newspaper Publication

    3 Jul 2025, 2:44PM Solara Active Pharma Sciences Limited has informed the exchange about copy of the Newspaper publications made by the Company with respect to dispatch
  • Solara Active Pharma - Updates

    2 Jul 2025, 11:57AM Solara Active Pharma Sciences Limited has informed the Exchange regarding Dispatch of First Reminder Notice for payment of First Call Money made on Ju
  • Solara Active Pharma - Dispatch Of First Reminder Notice For Payment Of First Call Money

    2 Jul 2025, 11:49AM Solara Active Pharma Sciences Limited has informed the Exchange about the dispatch of First Reminder Notice for payment of First Call Money sent on Ju
  • Solara Active Pharma - Credit Rating

    1 Jul 2025, 5:32PM Solara Active Pharma Sciences Limited has informed the Exchange about Credit Rating
  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Credit Rating

    1 Jul 2025, 5:20PM Solara Active Pharma Sciences Limited has informed Stock Exchange regarding Credit Rating received from Crisil Ratings Limited
  • Solara Active Pharma - Trading Window-XBRL

    27 Jun 2025, 3:59PM SOLARA ACTIVE PHARMA SCIENCES LIMITED has informed the Exchange about Closure of Trading Window
  • Solara Active Pharma - Trading Window

    27 Jun 2025, 3:56PM Solara Active Pharma Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)
  • Solara Active Pharma - Disclosure under SEBI Takeover Regulations

    26 Jun 2025, 9:42PM Solara Active Pharma Sciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board o
  • Solara Active Pharma

    6 Jul 2023 , 10:51AM Solara Active Pharma has agreed to raise funds through the issue of equity shares of FV of Rs. 10 not exceeding Rs. 450 Cr. by the way of rights issue to eligible equity shareholder of the company. We do not have coverage on it.
  • Solara Active Pharma successfully completes EU GMP Inspection

    13 Feb 2023 , 12:14PM Completion of the EU-GMP inspection at the Cuddalore facility of the Company
  • Stock Update: Solara Active Pharma Science

    12 Nov 2021 , 11:50AM Stock Update: Solara Active Pharma Science Q2FY22 Results Update
  • Solara Active Pharma Sciences Q2Fy22 results

    11 Nov 2021 , 5:14PM Solara Active Pharma Sciences Q2Fy22 results – Weak quarter, results missed estimates
  • Solara Active Pharma Sciences: Q1FY22 Results update

    5 Aug 2021 , 10:59AM Solara Active Pharma Sciences Ltd: Q1FY22 Results update - Healthy quarter; Robust outlook
  • Solara Active Pharma Sciences Q1FY2022

    4 Aug 2021 , 3:31PM Solara Active Pharma Sciences Q1FY2022: Healthy quarter; results miss estimates
  • Solara announces CEP for Ranitidine Hydrochloride drug substance restored by EDQM

    2 Jul 2021 , 3:31PM Solara is the first company to have its CEP restored among Ranitidine API manufacturers
  • Solara Active Pharma Sciences

    2 Jul 2021 , 3:19PM Solara Active Pharma Sciences: Has announced that the EDQM ( European Directorate for the Quality of Medicines & HealthCare) has restored is CEP for Ranitidine Hydrochloride drug substance (API). Solara had put in place robust manufacturing and quality processes to mitigate the risks of N-Nitroso Dimethylamine (NDMA) formation in the Ranitidine HCL API and subsequent submission of the pertinent data has fast-tracked the restoration of CEP by EDQM. Solara is the only company to have its CEP for Ranitidine hydrochloride restored, hence positive
  • Solara Active Pharma Sciences

    1 Jun 2021 , 10:27AM The government of India has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs. It envisages setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30.Now the Government has approved the application of 4 wait listed players who were eligible under the scheme. These include Solara Active Pharma Sciences, while the other companies being approved are Rajasthan Antibiotics Ltd, Dhatri Lab Pvt Ltd and Vital Laboratories Pvt Ltd. The products for which the approvals have been given are 1 Cyclohexane Diacetic Acid, Meropenem, Ritonavir and Levofloxacin. The receipt of the approval for PLI scheme is positive for Solara Active Pharma Sciences.
  • Solara Active Pharma Sciences: Q4FY2021 Result Update

    7 May 2021 , 11:10AM Solara Active Pharma Sciences: Q4FY2021 Result Update - Strong quarter; Robust outlook
  • Stock update - Solara Active Pharma Sciences

    13 Apr 2021 , 11:03AM Stock update - Solara Active Pharma Sciences : Synergetic Merger, Earnings accretive
  • Solara Active Pharma Sciences board approves merger of Aurore Life sciences

    12 Apr 2021 , 12:12PM Solara Active, Aurore Life combine to create second largest Pure Play API / CRAMs company in India
  • Solara Active Pharma Sciences

    12 Apr 2021 , 10:18AM Solara Active Pharma Sciences (Solara): Board approves merger of Aurore Life sciences in an all-stock deal; combined entity to be pure play API company of scale with strong presence in key markets, broad product portfolio and could strengthen Solara’s CRAMS business. We believe the merger would be positive as both the business are synergistic and would open up multiple growth avenues and enable to achieve operational efficiencies
  • Solara Active Pharma Sciences

    19 Feb 2021 , 9:09AM As per media news, The promoters along with TPG capital are said to be looking for an exit from the company. The total promoters stake stands at 44% while TPG Group had a stake of around 15%. The stake sale is likely to trigger an open offer.
  • Solara Active Pharma Sciences : Stock Update

    9 Dec 2020 , 12:04PM Solara Active Pharma Sciences : Stock Update – Growth Levers Intact
  • Solara Active Pharma announces interim dividend

    11 Nov 2020 , 12:20PM Solara Active Pharma Sciences board declares interim dividend of Rs. 4
  • Solara Active Pharma reports good Q2 earnings

    30 Oct 2020 , 3:12PM Solara Active Pharma: Strong operating performance leads to PAT beat
  • Solara Active Pharma Sciences

    16 Sep 2020 , 10:08AM Promoters Pronomz Ventures released pledge of 13.18 lakh shares on September 10, 2020. Post the release the proportion of pledged shares stands at 4.7% of the total promoters holdings down from 13%. The release of the pledged shares is positive
  • New Idea - Solara Active Pharma Sciences

    14 Sep 2020 , 11:40AM New Idea - Solara Active Pharma Sciences – Viewpoint - Well placed to harness API opportunities
  • Solara Active Pharma completes USFDA inspection at SRC

    17 Dec 2018 , 11:35AM Solara Research Centre (SRC) completes USFDA Inspection with Zero 483s

Key fundamentals

Evaluate the intrinsic value of Solara Active Pharma Sciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1872.27 1936.8 2504.28 2551.62 2108.49
Liabilities 1872.27 1936.8 2504.28 2551.62 2108.49
Equity 40.25 36 36 36 35.92
Gross Profit 203.84 -95.06 134.04 80.35 385.33
Net Profit -1.08 -566.87 -22.21 -58.56 220.96
Cash From Operating Activities 212.8 110.95 156.17 -241.77 154.44
NPM(%) -0.08 -43.98 -1.53 -4.61 13.66
Revenue 1283.76 1288.92 1443.81 1268.34 1616.88
Expenses 1079.92 1383.98 1309.77 1187.99 1231.55
ROE(%) -0.09 -51.86 -2.03 -5.35 20.21

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
18 Aug 2021 3 30 0 1648.75
19 Nov 2020 4 40 0 1095.5
28 Jul 2020 2 20 0 502.4
06 Aug 2019 5 50 0 442.1

Peers

Other companies within the same industry or sector that are comparable to Solara Active Pharma Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.85 0.88 73.51 378.79 301.39 0.62
Lotus Eye Hospital and Institute Ltd 120.00 -1.15 387.10 1380.25 3.55 0.00
Vaishali Pharma Ltd 12.09 0.33 403.00 711.43 3.13 0.00
Astec Lifesciences Ltd 855.00 0.30 0.00 1301.61 -604.77 0.00

Company Info

Our Company was originally incorporated on February 23, 2017 under the Companies Act, 2013 as SSL Pharma Sciences Limited with the RoC. The name of the Company was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC on March 25, 2017. 2019 -Solara Active Pharma Sciences Limited said that, “it has successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s i 2021 -Solara Active Pharma approves acquisition of balance 10.77% stake in Sequent Penems 2023 -Solara Active Pharma Sciences completes WHO inspection at its Cuddalore facility. 2024 -The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.

Our Company was originally incorporated on February 23, 2017 under the Companies Act, 2013 as SSL Pharma Sciences Limited with the RoC. The name of the Company was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC on March 25, 2017. 2019 -Solara Active Pharma Sciences Limited said that, “it has successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s i 2021 -Solara Active Pharma approves acquisition of balance 10.77% stake in Sequent Penems 2023 -Solara Active Pharma Sciences completes WHO inspection at its Cuddalore facility. 2024 -The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.

Read More

Parent Organisation

Solara Active Pharma Sciences Ltd.

Founded

23/02/2017

Managing Director

Mr.Poorvank Purohit

NSE Symbol

SOLARAEQ

FAQ

The current price of Solara Active Pharma Sciences Ltd is ₹ 686.75.

The 52-week high for Solara Active Pharma Sciences Ltd is ₹ 688.00 and the 52-week low is ₹ 662.20.

The market capitalization of Solara Active Pharma Sciences Ltd is currently ₹ 3054.00. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Solara Active Pharma Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Solara Active Pharma Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Solara Active Pharma Sciences Ltd shares.

The CEO of Solara Active Pharma Sciences Ltd is Mr.Poorvank Purohit, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT